Duligotuzumab

From WikiMD.org
Jump to navigation Jump to search

Duligotuzumab

Duligotuzumab (pronunciation: doo-li-goh-TOO-zoo-mab) is a monoclonal antibody designed for the treatment of cancer. It is a type of biological therapy that targets the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).

Etymology

The name "Duligotuzumab" is derived from the International Nonproprietary Names (INN), where "zu" denotes humanized, "mab" stands for monoclonal antibody, and "Duli" is a unique stem.

Mechanism of Action

Duligotuzumab works by binding to the EGFR and HER2 on the surface of cancer cells, blocking them from receiving growth signals. This inhibits the growth and division of the cancer cells, and may also stimulate the body's immune system to attack the cancer cells.

Related Terms

Clinical Trials

Duligotuzumab has been studied in clinical trials for the treatment of various types of cancer, including colorectal cancer, head and neck cancer, and non-small cell lung cancer (NSCLC). However, as of now, it is not yet approved by the Food and Drug Administration (FDA) or any other regulatory authority.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski